Escuela de Medicina, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.
Clínica Psiquiátrica Universitaria, Hospital Clínico de la Universidad de Chile, Universidad de Chile, Santiago 8380453, Chile.
Int J Mol Sci. 2023 Sep 30;24(19):14810. doi: 10.3390/ijms241914810.
Brain-derived neurotrophic factor (BDNF) has been studied as a biomarker of major depressive disorder (MDD). Besides diagnostic biomarkers, clinically useful biomarkers can inform response to treatment. We aimed to review all studies that sought to relate BDNF baseline levels, or BDNF polymorphisms, with response to treatment in MDD. In order to achieve this, we performed a systematic review of studies that explored the relation of BDNF with both pharmacological and non-pharmacological treatment. Finally, we reviewed the evidence that relates peripheral levels of BDNF and BDNF polymorphisms with the development and management of treatment-resistant depression.
脑源性神经营养因子(BDNF)已被研究作为重度抑郁症(MDD)的生物标志物。除了诊断生物标志物外,临床有用的生物标志物还可以告知对治疗的反应。我们旨在综述所有旨在将 BDNF 基线水平或 BDNF 多态性与 MDD 治疗反应相关联的研究。为了实现这一目标,我们对探索 BDNF 与药物和非药物治疗之间关系的研究进行了系统综述。最后,我们回顾了与外周 BDNF 水平和 BDNF 多态性与治疗抵抗性抑郁症的发展和管理相关的证据。